BioPharmSignal logoBioPharmSignal

Biotech News

Aprea Therapeutics Provides ACESOT-1051 Program Update for WEE1 Inhibitor APR-1051: Accelerating and Expanding Enrollment. Clinical Data Presentation Planned for Q4 2026

Aprea Therapeutics (APRE)Aprea TherapeuticsConference / presentation

Next clinical data update from the ongoing Phase 1 dose escalation ACESOT-1051 trial anticipated at a medical meeting in Q4 2026, providing a near-term opportunity to demonstrate continued clinical progress with APR-1051 Enrollment in ACESOT-1051 is accelerating as the Company advances dose

Related news

APREAprea Therapeutics2026-06-01 12:00 EST

Aprea Therapeutics Presents Updated Phase 1 Data on WEE1 Inhibitor APR-1051 at ASCO 2026, Demonstrating Early Monotherapy Activity and Manageable Tolerability in Advanced Solid Tumors

CMPXCompass Therapeutics2026-07-17 14:42 EST

Compass Therapeutics Announces Tovecimig Data Accepted for an Oral Presentation at the ESMO Congress 2026

RVMDRevolution Medicines2026-06-24 23:31 EST

Revolution Medicines to Present Clinical Data from RAS(ON) Inhibitor Combination Trials in Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026

REPLReplimune Group2026-05-31 12:00 EST

Replimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

COGTCogent Biosciences2026-06-12 12:01 EST

Cogent Biosciences Announces Preclinical Data from Novel JAK2 V617F Inhibitor at the 2026 European Hematology Association (EHA) Congress

LYELLyell Immunopharma2026-06-25 12:00 EST

Lyell Immunopharma Announces Participation in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference

LYELLyell Immunopharma2026-06-01 12:00 EST

Lyell Immunopharma Announces Participation in Goldman Sachs 47th Annual Global Healthcare Conference 2026

ZNTLZentalis2026-07-17 20:15 EST

Zentalis Pharmaceuticals to Present at the European Society for Medical Oncology (ESMO) Congress 2026

KURAKura Oncology2026-07-14 11:02 EST

Kura Oncology to Present First Long-Term Follow-Up Data Further Supporting Darlifarnib’s Potential to Enhance VEGFR-Targeted Therapy in Renal Cell Carcinoma at KCRS 2026

TEVATeva Pharmaceutical Industries2026-06-01 20:30 EST

Teva to Present at the Goldman Sachs Global Healthcare Conference

View all latest news

Aprea Therapeutics

DNA Damage Response Oncology Company Aprea Therapeutics develops precision medicines targeting vulnerabilities in cancer-cell DNA replication and repair. APR-1051 APR-1051 is a selective WEE1 inhibitor being evaluated in the Phase 1/2 ACESOT-1051 study for advanced solid tumors. Biomarker-Directed Expansion Development is expanding in...

Recent company news

APREAprea Therapeutics2026-07-30 12:00 EST

Aprea Therapeutics Provides ACESOT-1051 Program Update for WEE1 Inhibitor APR-1051: Accelerating and Expanding Enrollment. Clinical Data Presentation Planned for Q4 2026

APREAprea Therapeutics2026-06-01 12:00 EST

Aprea Therapeutics Presents Updated Phase 1 Data on WEE1 Inhibitor APR-1051 at ASCO 2026, Demonstrating Early Monotherapy Activity and Manageable Tolerability in Advanced Solid Tumors

APREAprea Therapeutics2026-05-13 10:30 EST

Aprea Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update

APREAprea Therapeutics2026-04-21 14:15 EST

Aprea Therapeutics to Provide Clinical Update on ACESOT-1051 Phase 1 Trial Evaluating WEE1 Inhibitor, APR-1051, at ASCO 2026 Annual Meeting

APREAprea Therapeutics2026-04-01 12:31 EST

Aprea Therapeutics Announces Closing of Oversubscribed $30 Million Private Placement

Stock data

Close
0.63 USD
Market cap
9.46M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States